Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease (Q35821201)

10 August 2017

1 reference

title

Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease (English)

1 reference

10 August 2017

Gilgun-Sherki Y

1

1 reference

10 August 2017

Djaldetti R

series ordinal

2

1 reference

10 August 2017

Melamed E

series ordinal

3

1 reference

10 August 2017

Offen D

series ordinal

4

1 reference

10 August 2017

publication date

1 January 2004

1 reference

The Pharmacogenomics Journal

10 August 2017

published in

1 reference

10 August 2017

volume

4

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

291-306

1 reference

Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

21 January 2018

Dystonia and dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Cloning of the cDNA and gene for a human D2 dopamine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Human dopamine D1 receptor encoded by an intronless gene on chromosome 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Chromosomal localization of the human D3 dopamine receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

The Dopamine D2 Receptor Locus as a Modifying Gene in Neuropsychiatric Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Genetic polymorphism of dopamine D2 receptors in Parkinson's disease and interactions with cigarette smoking and MAO-B intron 13 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Variability and validity of polymorphism association studies in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Parkinsonism-inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

The dopamine transporter gene and Parkinson's disease in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Association of the dopamine transporter gene with Parkinson's disease in Korean patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson's disease for male, but not to female patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Association between dopamine transporter gene polymorphism and susceptibility to Parkinson's disease in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

No evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Association study for Parkinson's disease and a dopamine transporter gene polymorphism (1215A/G).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Specification of catecholaminergic and serotonergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Parkinson's disease and CYP2D6 polymorphism in Asian populations: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

P450 enzymes and Parkinson's disease: the story so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Genetic polymorphism of the CYP2E1 gene and susceptibility to Parkinson's disease in Taiwanese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Lack of association between cytochrome P450 2E1 gene polymorphisms and Parkinson's disease in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Parkinson's disease, pesticides, and glutathione transferase polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Glutathione S-transferase M1, T1, and P1 polymorphisms and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

N-acetyltransferase-2 polymorphism in Parkinson's disease: the Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Apolipoprotein E and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Senile dementia of the Lewy body type has an apolipoprotein E epsilon 4 allele frequency intermediate between controls and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Apolipoprotein E genes in Lewy body and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Apolipoprotein E polymorphism in patients with different neurodegenerative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Frequency of the apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Apolipoprotein E genotyping in patients with neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Apolipoprotein E epsilon4 allele and progression of cortical Lewy body pathology in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Apolipoprotein E epsilon4 allele frequency is increased in Parkinson's disease only with co-existing Alzheimer pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Apolipoprotein E genotypes and age at onset of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Point mutations of mitochondrial genome in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Association between a polymorphism of brain-derived neurotrophic factor gene and sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Mutation analysis of the glial cell line-derived neurotrophic factor gene in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's di

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Genetic polymorphisms of superoxide dismutase in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Meta-analysis of alpha synuclein/ NACP polymorphism in Parkinson's disease in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

A novel polymorphic triplet repeat in intron five of the alpha-synuclein gene: no evidence of expansion or allelic association with idiopathic Parkinson's disease in the Irish

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Functional association of the parkin gene promoter with idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Parkin variants in North American Parkinson's disease: cases and controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Mutation screening and association analysis of the parkin gene in Parkinson's disease patients from South-West China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Association study of Parkin gene polymorphisms with idiopathic Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

NURR1 promoter polymorphisms: Parkinson's disease, schizophrenia, and personality traits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Success and problems of long-term levodopa therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Levodopa-induced dyskinesia: review, observations, and speculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Pathogenesis of dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Functional interaction of dopamine and glutamate in the nucleus accumbens in the regulation of locomotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Catechol-O-methyltransferase activity: a determinant of levodopa response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

CYP2D6 polymorphism in Parkinson's disease: The Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: Evidence for an age-dependent relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Dopamine receptor D2 intronic polymorphism in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

alpha-synuclein gene haplotypes are associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

No Association between Parkinson's Disease and Low-Activity Alleles of CatecholO-Methyltransferase

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

21 January 2018

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

The Relationship between COMT Genotype and the Clinical Effectiveness of Tolcapone, a COMT Inhibitor, in Patients with Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

Pathophysiology of movement disorders studied using PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

1 reference

7 January 2021

No allelic association between Parkinson's disease and dopamine D2, D3, and D4 receptor gene polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Lack of allelic association of dopamine D4 receptor gene polymorphisms with Parkinson's disease in a chinese population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Dopamine D4 receptor polymorphism and idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Association of long variants of the dopamine D4 receptor exon 3 repeat polymorphism with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

1 reference

7 January 2021

Variable number tandem repeat dopamine transporter gene polymorphism and Parkinson's disease: no association found

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Tyrosine hydroxylase polymorphism in familial and sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Detection and analysis of four polymorphic markers at the human monoamine oxidase (MAO) gene in Japanese controls and patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

No association between Parkinson's disease and monoamine oxidase A and B gene polymorphisms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Association of a monoamine oxidase B allele with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

1 reference

7 January 2021

Association analysis of a polymorphism of the monoamine oxidase B gene with Parkinson's disease in a Japanese population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

An allelic association study of monoamine oxidase B in parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: a study in an Asian population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Determination of catechol O-methyltransferase activity in relation to melanin metabolism using high-performance liquid chromatography with fluorimetric detection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan. Short communication.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and Parkinsonian patients in Finland

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson's disease in Finland

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

1 reference

7 January 2021

Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

1 reference

7 January 2021

Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

1 reference

7 January 2021

CYP2D6 polymorphism and Parkinson's disease susceptibility

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Parkinson's disease, CYP2D6 polymorphism, and age

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Genetic association between cytochrome P450IA1 gene and susceptibility to Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Lack of association between CYP1A1 polymorphism and Parkinson's disease in a Chinese population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Case-control study of interactions between genetic and environmental factors in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

N-acetyltransferase 2 polymorphism in sporadic Parkinson's disease in a Polish population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

1 reference

7 January 2021

Acetylator genotype and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Apolipoprotein E gene in Parkinson's disease with or without dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Genetic study of apolipoprotein E gene, alpha-1 antichymotrypsin gene in sporadic Parkinson disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

The apolipoprotein epsilon 4 allele in Parkinson's disease with and without dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Apolipoprotein E genotypes in Parkinson's disease with and without dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Apolipoprotein E and B alleles in Parkinson's patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Apolipoprotein E polymorphisms and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Analysis of mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson disease patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

NACP-REP1 polymorphism is not involved in Parkinson's disease: a case-control study in a population sample from southern Italy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

1 reference

7 January 2021

Association of codon 167 Ser/Asn heterozygosity in the parkin gene with sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Polymorphisms of the parkin gene in sporadic Parkinson's disease among Chinese in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Genetic analysis of Nurr1 haplotypes in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Age at onset: the major determinant of outcome in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

1 reference

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

1 reference

7 January 2021

Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500260

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500260

1 reference

10 August 2017

1 reference